Nuvalent is a clinical stage biopharma company that develops treatments for cancer patients. CEO James Porter weighs in on the FDA breakthrough therapy designation for NVL-655. The latest NUVL earnings report indicated an EPS of -$0.69.
Morning Trade Live
17 Jun 2024
SHARE